Cargando…

Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Detalles Bibliográficos
Autores principales:	Nichols, Russell, Skljarevski, Vladimir, Dell’Agnello, Grazia, Hundemer, Hans-Peter, Aurora, Sheena K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734426/ https://www.ncbi.nlm.nih.gov/pubmed/30823868 http://dx.doi.org/10.1186/s10194-019-0975-2

Ejemplares similares

Letter to the editor: European headache federation guidelines on the use of monoclonal antibodies acting on the calcitonin gene-related peptide or its receptor for migraine prevention
por: Mikol, Daniel D., et al.
Publicado: (2019)

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Sacco, Simona, et al.
Publicado: (2019)

Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Sacco, Simona, et al.
Publicado: (2019)

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
por: Sacco, Simona, et al.
Publicado: (2022)

Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea
por: Kim, Byung-Kun, et al.
Publicado: (2021)

Correction to: Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea
por: Kim, Byung-Kun, et al.
Publicado: (2021)

Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study
por: Pascual, Julio, et al.
Publicado: (2023)

Prevalence Rates of Primary Headache Disorders and Evaluation and Treatment Patterns Among Korean Neurologists
por: Kim, Byung-Kun, et al.
Publicado: (2022)

Correction: Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study
por: Pascual, Julio, et al.
Publicado: (2023)

Letter to the editor regarding “To what extent are patients with migraine able to predict attacks?”
por: Fang, Xiang, et al.
Publicado: (2018)

Letter to the Editor: Frequency of Visual Aura in Non-Migraine Headache Strongly Depends on the Underlying Pathophysiology
por: Finsterer, Josef
Publicado: (2023)

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
por: Morgan, Kelsey Woods, et al.
Publicado: (2021)

Response to letter to the editor “Calcitonin gene-related peptide and traumatic brain injury”
por: Jia, Pi-Feng
Publicado: (2019)

Letter to Editor Regarding the OCEAN Study [Letter]
por: Yawn, Barbara P, et al.
Publicado: (2021)

Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process
por: Steiner, Timothy J, et al.
Publicado: (2022)

European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA)
por: Sacco, Simona, et al.
Publicado: (2020)

Risk of placental abruption in relation to migraines and headaches
por: Sanchez, Sixto E, et al.
Publicado: (2010)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide and Its Receptor in Japanese Adolescents With Migraines
por: Katsuki, Masahito, et al.
Publicado: (2023)

Letters to the Editor
por: Nichols, Constance
Publicado: (1962)

Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance
por: Sacco, Simona, et al.
Publicado: (2021)

Letter to the Editor Regarding Vaping Article
por: Spitz, Rabbi Yehuda
Publicado: (2019)

Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension
por: Yiangou, Andreas, et al.
Publicado: (2020)

CDF II integrated calorimetry environment
por: Dell'Agnello, S
Publicado: (2002)

Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials
por: Stauffer, Virginia L., et al.
Publicado: (2019)

Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
por: Cohen, Fred, et al.
Publicado: (2022)

Response letter regarding the letter to the editors by Brown et al.
por: Taylor, Sylvia, et al.
Publicado: (2016)

Gleaning after the European Headache Federation consensus statement on refractory chronic migraine
por: Martelletti, Paolo, et al.
Publicado: (2014)

Letter to the editor: Regarding the editorial by Penttinen and Friede
por: Fry, Alicia M, et al.
Publicado: (2016)

Comparing the Efficacy, Safety, and Superiority of Calcitonin Gene-Related Peptide Monoclonal Antibodies and Botox in Preventing and Treating Migraines
por: Siddiqui, Mariah, et al.
Publicado: (2021)

Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

Letter to the Editor Regarding “Letter to the Editor: Spinal and Neurosurgical Publications During the COVID-19 Era”
por: Akhaddar, Ali, et al.
Publicado: (2020)

Letter to the Editor: The Case for Publicly Funded Headache Surgery in Germany
por: Knoedler, Leonard, et al.
Publicado: (2021)

Calcitonin Gene-Related Peptide in Tension-Type Headache
por: Ashina, M.
Publicado: (2002)

Calcitonin Gene-Related Peptide in Tension-Type Headache
por: Ashina, Messoud
Publicado: (2001)

Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache
por: Carmine Belin, Andrea, et al.
Publicado: (2020)

Correction: Comparing the Efficacy, Safety, and Superiority of Calcitonin Gene-Related Peptide Monoclonal Antibodies and Botox in Preventing and Treating Migraines
por: Siddiqui, Mariah, et al.
Publicado: (2021)

Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
por: Pavelic, Antun R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nm4q6uuiksv0udm15bij3vtks2